7 October 2020 - European countries are facing shortages of COVID-19 drug remdesivir because limited supplies are running out, officials said, with cases surging and the United States having bought up most of drugmaker Gilead’s output.

In July, the 27 European Union countries and Britain, with a combined population of 500 million, secured doses to treat about 30,000 patients. The United States signed a deal for more than 500,000 courses of treatment, accounting for most of Gilead’s output through September.

“Remdesivir has run out,” Dutch Health Ministry spokesman Martijn Janssen told Reuters, adding however that new deliveries were expected shortly.

Read Reuters article